Therapeutic Vaccines for Genitourinary Malignancies
AbstractThe field of genitourinary malignancies has been a showcase for therapeutic cancer vaccine success since the application of intravesicular Bacillus Calmette-Guerin (BCG) for bladder cancer in the 1970s and enjoyed a renaissance in 2010 with the US Food and Drug Administration (FDA) approval of sipuleucel-T for prostate cancer. Several vaccine strategies have emerged, such as autologous or allogeneic whole-tumor vaccines, DNA vaccines, use of viral vectors, and peptides as immunostimulatory adjuvants. Despite impressive early trials, vaccine monotherapy has achieved limited success in the clinical world; however, combinations of vaccine and immune checkpoint inhibition or vaccine and cytokine stimulation are expected to move the field forward. This article reviews pivotal trials of cancer vaccines in prostate, renal, and bladder cancer and ongoing trials combining vaccines with other immune therapy agents. View Full-Text
Share & Cite This Article
Dutcher, G.M.A.; Bilen, M.A. Therapeutic Vaccines for Genitourinary Malignancies. Vaccines 2018, 6, 55.
Dutcher GMA, Bilen MA. Therapeutic Vaccines for Genitourinary Malignancies. Vaccines. 2018; 6(3):55.Chicago/Turabian Style
Dutcher, Giselle M.A.; Bilen, Mehmet A. 2018. "Therapeutic Vaccines for Genitourinary Malignancies." Vaccines 6, no. 3: 55.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.